Bernanke Spurs Stocks
Health Care: Drugs
PDL BioPharma Inc. (PDLI: NASDAQ)
$8.26 -0.11 | -1.31%
05/22/13 - 04:00 PM ET
Company Profile
| Price and Volume | |
|---|---|
| Recent Price | 8.37 |
| 52 Week High | 8.43 |
| 52 Week Low | 6.18 |
| Avg. Daily Vol. (Mil) | 1.79 |
| Beta (3 year) | 0.51 |
| Share Related Items | |
| Mkt Cap (Mil) | 1,171.77 |
| Shares Out (Mil) | 140.00 |
| Float (Mil) | 121.97 |
| Dividend Information | |
| Yield % | 7.20 |
| Annual Dividend | 0.60 |
| Payout Ratio | 38.00 |
| Financial Strength | |
| Quick Ratio | 3.40 |
| Current Ratio | 3.80 |
| LT Debt/ Equity | 0.00 |
| Total Debt / Equity | n.a. |
| Valuation Ratios | |
| Price Earnings | 5.30 |
| Price/Sales | 3.01 |
| Price/Book | 0.00 |
| Price/Cash Flow | 4.90 |
| Per Share Data | |
| Earnings | 1.57 |
| Sales | 2.78 |
| Book Value | 0.00 |
| Cash Flow | 1.71 |
| Business Summary | |
|---|---|
| PDL BioPharma, Inc., is involved in the discovery of a new generation of targeted treatments for cancer and immunologic diseases. | |
| General Information | |
| 932 Southwood Boulevard
Incline Villiage, NV 89451 |
|
| www.pdl.com | |
| Industry : Drugs | |
| Sector: Health Care | |
| Employees: 10 | |
| CEO: Mr. John P. Mclaughlin | |
| Short Interest | |
| Current Month (Mil) | 22.33 |
| Previous Month (Mil) | 21.58 |
| Short Interest Ratio (Days) | 12.90 |
| Management Effectiveness | |
| Return on Equity | n.a. |
| Return on Assets | 71.90 |
| Return on Investments | 102.00 |
| Profitability | |
| Gross Margin | n.a. |
| EBIT Margin | 92.60 |
| Profit Margin | 57.80 |
Portfolios with PDLI
- Portfolio NameUser Type
- ProHighbridge Capital Management
- ContributorEarnings Short Squeeze Play...
- UserSm. Magic July 5 13
- UserMy Stuff
- Userdgr008 Portfolio 1
- ContributorHighest-Yielding Drug Stocks
- UserDividend
- Contributor18 Fundamentally Strong Sto...
- UserGK13
- UserMy current
Latest PDLI Headlines from TheStreet
- 'Mad Money' Lightning Round: Ford Is a Buy 05.16.13 | 06:05 am
- Cramer's 'Mad Money' Recap: Google vs. Apple 05.15.13 | 07:05 pm
- 4 Buy-Rated Dividend Stocks: COP, ETE, PDLI, TEG 05.10.13 | 11:05 am
- 3 Buy-Rated Dividend Stocks 04.26.13 | 11:04 am
- PDL BioPharma (PDLI) Shares Cross Below 200 DMA 04.17.13 | 12:04 pm
- 5 Buy-Rated Dividend Stocks 04.16.13 | 11:04 am
- 3 Buy-Rated Dividend Stocks 04.04.13 | 11:04 am
- 2 Drug Stocks Under $10 To Pick As Favorites 03.25.13 | 02:03 pm
- 'Mad Money' Lightning Round: Stay Away From Intel 11.06.12 | 06:11 am
- Cramer's 'Mad Money' Recap: Politics Is Overrated 11.05.12 | 08:11 pm
Press Releases for PDLI
- PDL BioPharma To Announce First Quarter 2013 Financial Results On May 9, 2013 - PR Newswire 05.02.13 | 07:05 am
- PDL BioPharma Appoints Peter Garcia As Chief Financial Officer - PR Newswire 04.30.13 | 04:04 pm
- PDL BioPharma Completes Structured Financing And Royalty Transaction With Avinger - PR Newswire 04.22.13 | 12:04 pm
- PDL BioPharma Completes Regular Quarterly Dividend Payment - PR Newswire 03.12.13 | 04:03 pm
- PDL BioPharma To Hold Annual Meeting Of Stockholders On May 21, 2013 - PR Newswire 03.06.13 | 04:03 pm
- PDL BioPharma Announces Conversion Rate Adjustments For Convertible Notes - PR Newswire 03.04.13 | 07:03 am
- PDL BioPharma To Announce Fourth Quarter And Full Year 2012 Financial Results On March 1, 2013 - PR Newswire 02.25.13 | 04:02 pm
- PDL BioPharma To Present At Two Upcoming Investor Conferences - PR Newswire 02.20.13 | 07:02 am
- PDL BioPharma Announces 2013 Regular Quarterly Dividends - PR Newswire 01.30.13 | 07:01 am
- PDL BioPharma Announces Departure Of Finance VP - PR Newswire 01.30.13 | 06:01 am
Partner Headlines for PDLI
- 10 Sharp Healthcare Dogs Diagnose 7.4% To 62.1% Gains In March - Seeking Alpha 04.01.13 | 09:04 am
- After-Hours Earnings Report for March 1, 2013 : VNR, PDLI - NASDAQ 03.01.13 | 07:03 pm
- PDL BioPharma, Inc. (PDLI) Ex-Dividend Date Scheduled for March 01, 2013 - NASDAQ 02.27.13 | 02:02 pm
- 8 High-Yielding Dividend Stocks With Very Low PEG Ratios - Seeking Alpha 12.30.12 | 09:12 am
- PDL BioPharma, AxoGen Benefit From 'Royal' Agreement - Seeking Alpha 11.20.12 | 09:11 am
- UPDATE: Credit Suisse Initiates PDL Biopharma at Neutral on Dividend Continuity Questions - Benzinga 11.13.12 | 01:11 pm
- These 2 Cramer High-Yield Picks Are Worth Buying In The Market Pullback - Seeking Alpha 11.08.12 | 09:11 am
- Cramer's Lightning Round - Heckmann Is Still A Good Spec (9/28/12) - Seeking Alpha 09.30.12 | 07:09 am
- PDLI Guides Q3 Royalty Rev to $85M - Analyst Blog - NASDAQ 09.07.12 | 08:09 pm
- PDL BioPharma Beats Zacks Estimates - Analyst Blog - Zacks 08.06.12 | 09:08 am
